

## PGY1 and PGY2 Oncology Research Projects

Class	Resident	Major Project
2024-2025	Mason Myers	<b>Bendamustine as Alternative Lymphodepletion for Chimeric Antigen Receptor T-cell Therapy (part 2)</b>
2024-2025	Megan Gadda	<b>Assessment of Pretreatment DPD/DPYD Testing for Fluoropyrimidine Chemotherapy</b>
2024-2025	Sheridan Bryan (PGY1)	Impact of low lymphocyte count on efficacy of BiTE therapy
2024-2025	Victoria Liu (PGY1)	Gemcitabine and Pazopanib for Advanced or Metastatic Soft Tissue Sarcoma
2023-2024	Sydney Ertz	<b>Glucarpi-CAP: A retrospective chart review of 1000 unit glucarpidase dosing for methotrexate rescue</b>
2023-2024	Arika Sandbach	<b>Bendamustine as Alternative Lymphodepletion for Chimeric Antigen Receptor T-cell Therapy</b>
2023-2024	Mason Myers (PGY1)	AKI post allogeneic transplantations
2023-2024	Megan Gadda (PGY1)	Assessment of Risk Associated with Hepatic Sinusoidal Obstructive Syndrome Post-Hematopoietic Stem Cell Transplant in Adult Patients
2022-2023	Gina Migneco	<b>Single-Center Experience of Clofarabine and Cytarabine in Children with Relapsed/Refractory Acute Myeloid Leukemia</b>
2022-2023	Elizabeth Ko	<b>Evaluation of Dose Reduction of Tyrosine Kinase Inhibitors Following Achievement of Major Molecular Response in Chronic Myeloid Leukemia</b>
2022-2023	Laura Klos (PGY1)	Safety and Efficacy of Tixagivemab/cilgavimab (Evusheld) in Patients Undergoing Hematopoietic Stem Cell Transplant
2022-2023	Sydney Ertz (PGY1)	Eltrombopag for Treatment of Thrombocytopenia after Hematopoietic Cell Transplantation or CAR-T Therapy
2021-2022	Philip Nguyen	<b>Determination of an Association Between Tyrosine Kinase Inhibitor Toxicity and Prior Immune Checkpoint Inhibitor Therapy</b>
2021-2022	Arthur Nguyen	<b>Breakthrough CMV Infection Rate and Survival Outcome of Letermovir Prophylaxis in Patients Undergoing Haploidentical Stem Cell Transplant with Post-Transplantation Cyclophosphamide</b>
2021-2022	Elizabeth Ko (PGY1)	Alternative capecitabine dosing strategies in metastatic breast cancer patients
2020-2021	Ngoc Nguyen	<b>Impact of weight on safety and efficacy outcomes with methotrexate for prevention of graft-versus-host disease</b>
2020-2021	Sean Badal	<b>Real-world safety outcomes of dose-adjusted lenvatinib</b>
2020-2021	Emily Chheng (PGY1)	Real world look at treatment-free remission in CML patients
2020-2021	Kat Kovalenko (PGY1)	Retrospective analysis of tacrolimus levels following allogeneic stem cell transplant
2019-2020	Sophia Ma	<b>Investigating the use of atropine as a premedication in patients treated with irinotecan</b>
2019-2020	Jonathan Cohen	<b>*Efficacy and safety of single-dose intravenous iron: Comparison of iron dextran and ferumoxytol</b>
2019-2020	Shelley Zhang (PGY1)	Barriers in the acquisition of oral anticancer medications

2018-19	Tina Gu	<b>Comparative effects of isavuconazole vs fluconazole vs posaconazole effects upon CYP inhibition</b>
2018-19	Lina Lin	<b>Implementation of CDTM for pharmacist-managed immune suppression therapy (IST) in the adult hematopoietic stem cell transplant (HSCT) ambulatory clinic</b>
2018-19	Chris Bell (PGY1)	Flu Vaccination in CML
2018-19	Jonathan Cohen (PGY1)	Liquid formulations of oncology drugs
2017-18	Jessica Lu	<b>Pain management among patients with hematologic malignancies</b>
2017-18	Jason Wing	<b>Retrospective assessment of a newly implemented guideline for ECG monitoring in hospitalized oncology patients at risk for drug induced prolonged QTc intervals</b>
2017-18	Shiela McCollam PGY1)	Pneumocystis pneumonia prophylaxis with intravenous pentamidine in adult allogeneic hematopoietic stem cell transplant patients
2016-17	Kelsey Mulverhill	<b>Evaluation of the efficacy and safety of rivaroxaban compared to enoxaparin for venous thromboembolism (VTE) prophylaxis in oncology patients status post abdominal surgery</b>
2016-17	Ai Thi Nguyen	<b>Clinical outcomes and cost analysis of reduced nilotinib dose intensity in chronic myeloid leukemia (CML)</b>
2016-17	Linda Blake (PGY1)	Intermittent versus continuous infusion of tacrolimus for prevention of graft-versus-host disease in hematopoietic stem cell transplant patients with hematologic malignancy
2016-17	Amanda Kurtti (PGY1)	Assessment of current practice and development of a guideline for ECG monitoring in hospitalized oncology patients at risk for drug induced prolonged QTc intervals
2015-16	Megan Saraceni	<b>*Retrospective review of modified HyperCVAD versus bortezomib-HyperCAD in patients with newly diagnosed or relapsed/refractory multiple myeloma at a single academic medical center</b>
2015-16	Jordan Miller (PGY1)	Current practice in managing febrile neutropenic patients with cefepime intolerance
2014-15	Aaron Pham	<b>*Comparison of trough levels from patients on posaconazole tablet and suspension for the treatment and prevention of fungal infections</b>
2014-15	Alex Heyliger (PGY1)	Assessment and optimization of current dosing practice for tacrolimus and cyclosporine for prevention of graft-versus-host disease in obese patients
2014-15	Gary Lau (PGY1)	Prospective characterization of CINV/severe nausea in oncology patients receiving chemotherapy
2013-14	Lauren Long	<b>Evaluation of leucovorin rescue dosing in patients receiving high dose methotrexate</b>
2013-14	Aaron Pham (PGY1)	Methotrexate monitoring in the neuro-oncology patients
2012-13	Jillian Paxton	<b>Standardization of chemotherapy dosing in obese population: a pilot implementation</b>
2011-12	Amber Diaz	<b>*Review, document, implement, and test safety and satisfaction with chemotherapy regimen templates in an electronic medical record with the goal of developing a standard for future regimen entry</b>
2011-12	Tammy Chan (PGY1)	Development and implementation of a patient counseling program
2011-12	Joshua Pecoraro (PGY1)	Bone marrow transplant discharge counseling